- Admin
- #1
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide ORIC-101 plasma concentrations provided excellent target coverage, consistent suppression of key glucocorticoid receptor (GR) biomarkers, and no evidence of drug-drug interaction impacting enzalutamide The addition of ORIC-101 after progression on single agent enzalutamide enabled continued enzalutamide treatment, with preliminary ev